Cidara Therapeutics Inc

Cidara Therapeutics — Technical Presentation (March 2018)

15 slides from Cidara Therapeutics's technical presentation, Mar 19, 2018

  1. Slide 1: STRIVE Part A Phase 2 topline data

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 STRIVE Part A Phase 2 topline data March 2018

  2. Slide 2: Cidara Pipeline Programs

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear Cidara Pipeline Programs Indication Discovery Research/ in vitro in vivo IND Enabling Phase 1 Phase 2 Phase 3 Rezafungin Treatment (Candida) Rezafungin Fungal Prophylaxis in alloBMT CloudbreakT

  3. Slide 3: STRIVE Part A: Candidemia & Invasive Candidiasis

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear STRIVE Part A: Candidemia & Invasive Candidiasis 400/400/(400)mg n=30 400/200/(200)mg n=30 Week 1 2 3 4 5 6 7 8 9 Day 1 5 8 15 22 28 Dose Optional dose Mycological response Mycological & clinic

  4. Slide 4: Major objectives of STRIVE Part A

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear Major objectives of STRIVE Part A Select a dosing regimen for STRIVE Part B and Phase 3 based on: • Clinical and mycological cure by time, severity and empiric treatment • Tolerability, safety

  5. Slide 5: Topline Baseline Characteristics ITT Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear 5 Topline Baseline Characteristics ITT Population Parameter Rezafungin 400 mg/400 mg (QWk) N= 35 Rezafungin 400 mg/200 mg (QWk) N= 36 Caspofungin 70 mg/50 mg (QD) N= 36 n (%) Age Mean age, yrs

  6. Slide 6: Topline Overall Response (Primary Outcome) Day 14 – mITT Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear 6 Topline Overall Response (Primary Outcome) Day 14 – mITT Population Response Rezafungin 400 mg/400 mg (QWk) N= 33 Rezafungin 400 mg/200 mg (QWk) N= 31 Caspofungin 70 mg/50 mg (QD) N= 28 n (%)

  7. Slide 7: Topline Investigator Assessment of Clinical Response Day 14 – mITT Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear 7 Topline Investigator Assessment of Clinical Response Day 14 – mITT Population Response Rezafungin 400 mg/400 mg (QWk) N= 33 Rezafungin 400 mg/200 mg (QWk) N= 31 Caspofungin 70 mg/50 mg (QD) N

  8. Slide 8: Topline Overall Response Day 5 – mITT Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear 8 Topline Overall Response Day 5 – mITT Population Response Rezafungin 400 mg/400 mg (QWk) N= 33 Rezafungin 400 mg/200 mg (QWk) N= 31 Caspofungin 70 mg/50 mg (QD) N= 28 n (%) Success 19 (57.6)

  9. Slide 9: Topline Overall Success by Severity and Prior Therapy Day 14 – mITT Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear 9 Topline Overall Success by Severity and Prior Therapy Day 14 – mITT Population Population Rezafungin 400 mg/400 mg (QWk) Rezafungin 400 mg/200 mg (QWk) Caspofungin 70 mg/50 mg (QD) n/N (%) Ov

  10. Slide 10: Topline Day 30 All-Cause Mortality (1º Endpoint for Ph3) mITT Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear Topline Day 30 All-Cause Mortality (1º Endpoint for Ph3) mITT Population Parameter Rezafungin 400 mg/400 mg (QWk) N= 33 Rezafungin 400 mg/200 mg (QWk) N= 31 Caspofungin 70 mg/50 mg (QD) N= 28 D

  11. Slide 11: Topline Summary of Adverse Events Safety Population

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear Topline Summary of Adverse Events Safety Population Parameter Rezafungin 400 mg/400 mg (QWk) N= 35 Rezafungin 400 mg/200 mg (QWk) N= 36 Caspofungin 70 mg/50 mg (QD) N= 33 n (%) ≥1 TEAE Severe 3

  12. Slide 12: STRIVE A Topline Conclusions

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear STRIVE A Topline Conclusions  Based on topline data, Phase 2 STRIVE trial met objectives with favorable safety and efficacy data for RZF in candidemia/IC to support advancing to Phase 3 clinic

  13. Slide 13: STRIVE Part B provides an early read on treatment Phase 3

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear STRIVE Part B provides an early read on treatment Phase 3 Seamless Phase 2 to Phase 3 Strategy Phase 2 STRIVE ( Part A ) Phase 2 STRIVE ( Part B ) Phase 3 ReSTORE Dosing Regimen Global , multic

  14. Slide 14: …two P3 studies, one in each population, with distinct commercial opportunities

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear …two P3 studies, one in each population, with distinct commercial opportunities Topline Phase 2 STRIVE A Data Phase 3 Treatment Trial Start Phase 3 Prophylaxis Trial Start Phase 3 Prophylaxis I

  15. Slide 15: Rezafungin Overall Phase 3 Development Plan

    186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Keep this area clear Keep this area clear Rezafungin Overall Phase 3 Development Plan Phase 3 Treatment Trial Indication Phase 3 Size Duration of therapy, Endpoints and Comparators Timing for initiation and data Treatment of Candidemia

Cidara Therapeutics — Technical Presentation (March 2018) on 6ix